Cargando…

Extracellular volume fraction mapping in the myocardium, part 2: initial clinical experience

BACKGROUND: Diffuse myocardial fibrosis, and to a lesser extent global myocardial edema, are important processes in heart disease which are difficult to assess or quantify with cardiovascular magnetic resonance (CMR) using conventional late gadolinium enhancement (LGE) or T1-mapping. Measurement of...

Descripción completa

Detalles Bibliográficos
Autores principales: Kellman, Peter, Wilson, Joel R, Xue, Hui, Bandettini, W Patricia, Shanbhag, Sujata M, Druey, Kirk M, Ugander, Martin, Arai, Andrew E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3442966/
https://www.ncbi.nlm.nih.gov/pubmed/22967246
http://dx.doi.org/10.1186/1532-429X-14-64
_version_ 1782243489342291968
author Kellman, Peter
Wilson, Joel R
Xue, Hui
Bandettini, W Patricia
Shanbhag, Sujata M
Druey, Kirk M
Ugander, Martin
Arai, Andrew E
author_facet Kellman, Peter
Wilson, Joel R
Xue, Hui
Bandettini, W Patricia
Shanbhag, Sujata M
Druey, Kirk M
Ugander, Martin
Arai, Andrew E
author_sort Kellman, Peter
collection PubMed
description BACKGROUND: Diffuse myocardial fibrosis, and to a lesser extent global myocardial edema, are important processes in heart disease which are difficult to assess or quantify with cardiovascular magnetic resonance (CMR) using conventional late gadolinium enhancement (LGE) or T1-mapping. Measurement of the myocardial extracellular volume fraction (ECV) circumvents factors that confound T1-weighted images or T1-maps. We hypothesized that quantitative assessment of myocardial ECV would be clinically useful for detecting both focal and diffuse myocardial abnormalities in a variety of common and uncommon heart diseases. METHODS: A total of 156 subjects were imaged including 62 with normal findings, 33 patients with chronic myocardial infarction (MI), 33 with hypertrophic cardiomyopathy (HCM), 15 with non-ischemic dilated cardiomyopathy (DCM), 7 with acute myocarditis, 4 with cardiac amyloidosis, and 2 with systemic capillary leak syndrome (SCLS). Motion corrected ECV maps were generated automatically from T1-maps acquired pre- and post-contrast calibrated by blood hematocrit. Abnormally-elevated ECV was defined as >2SD from the mean ECV in individuals with normal findings. In HCM the size of regions of LGE was quantified as the region >2 SD from remote. RESULTS: Mean ECV of 62 normal individuals was 25.4 ± 2.5% (m ± SD), normal range 20.4%-30.4%. Mean ECV within the core of chronic myocardial infarctions (without MVO) (N = 33) measured 68.5 ± 8.6% (p < 0.001 vs normal). In HCM, the extent of abnormally elevated ECV correlated to the extent of LGE (r = 0.72, p < 0.001) but had a systematically greater extent by ECV (mean difference 19 ± 7% of slice). Abnormally elevated ECV was identified in 4 of 16 patients with non-ischemic DCM (38.1 ± 1.9% (p < 0.001 vs normal) and LGE in the same slice appeared “normal” in 2 of these 4 patients. Mean ECV values in other disease entities ranged 32-60% for cardiac amyloidosis (N = 4), 40-41% for systemic capillary leak syndrome (N = 2), and 39-56% within abnormal regions affected by myocarditis (N = 7). CONCLUSIONS: ECV mapping appears promising to complement LGE imaging in cases of more homogenously diffuse disease. The ability to display ECV maps in units that are physiologically intuitive and may be interpreted on an absolute scale offers the potential for detection of diffuse disease and measurement of the extent and severity of abnormal regions.
format Online
Article
Text
id pubmed-3442966
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-34429662012-09-15 Extracellular volume fraction mapping in the myocardium, part 2: initial clinical experience Kellman, Peter Wilson, Joel R Xue, Hui Bandettini, W Patricia Shanbhag, Sujata M Druey, Kirk M Ugander, Martin Arai, Andrew E J Cardiovasc Magn Reson Research BACKGROUND: Diffuse myocardial fibrosis, and to a lesser extent global myocardial edema, are important processes in heart disease which are difficult to assess or quantify with cardiovascular magnetic resonance (CMR) using conventional late gadolinium enhancement (LGE) or T1-mapping. Measurement of the myocardial extracellular volume fraction (ECV) circumvents factors that confound T1-weighted images or T1-maps. We hypothesized that quantitative assessment of myocardial ECV would be clinically useful for detecting both focal and diffuse myocardial abnormalities in a variety of common and uncommon heart diseases. METHODS: A total of 156 subjects were imaged including 62 with normal findings, 33 patients with chronic myocardial infarction (MI), 33 with hypertrophic cardiomyopathy (HCM), 15 with non-ischemic dilated cardiomyopathy (DCM), 7 with acute myocarditis, 4 with cardiac amyloidosis, and 2 with systemic capillary leak syndrome (SCLS). Motion corrected ECV maps were generated automatically from T1-maps acquired pre- and post-contrast calibrated by blood hematocrit. Abnormally-elevated ECV was defined as >2SD from the mean ECV in individuals with normal findings. In HCM the size of regions of LGE was quantified as the region >2 SD from remote. RESULTS: Mean ECV of 62 normal individuals was 25.4 ± 2.5% (m ± SD), normal range 20.4%-30.4%. Mean ECV within the core of chronic myocardial infarctions (without MVO) (N = 33) measured 68.5 ± 8.6% (p < 0.001 vs normal). In HCM, the extent of abnormally elevated ECV correlated to the extent of LGE (r = 0.72, p < 0.001) but had a systematically greater extent by ECV (mean difference 19 ± 7% of slice). Abnormally elevated ECV was identified in 4 of 16 patients with non-ischemic DCM (38.1 ± 1.9% (p < 0.001 vs normal) and LGE in the same slice appeared “normal” in 2 of these 4 patients. Mean ECV values in other disease entities ranged 32-60% for cardiac amyloidosis (N = 4), 40-41% for systemic capillary leak syndrome (N = 2), and 39-56% within abnormal regions affected by myocarditis (N = 7). CONCLUSIONS: ECV mapping appears promising to complement LGE imaging in cases of more homogenously diffuse disease. The ability to display ECV maps in units that are physiologically intuitive and may be interpreted on an absolute scale offers the potential for detection of diffuse disease and measurement of the extent and severity of abnormal regions. BioMed Central 2012-09-11 /pmc/articles/PMC3442966/ /pubmed/22967246 http://dx.doi.org/10.1186/1532-429X-14-64 Text en Copyright ©2012 Kellman et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Kellman, Peter
Wilson, Joel R
Xue, Hui
Bandettini, W Patricia
Shanbhag, Sujata M
Druey, Kirk M
Ugander, Martin
Arai, Andrew E
Extracellular volume fraction mapping in the myocardium, part 2: initial clinical experience
title Extracellular volume fraction mapping in the myocardium, part 2: initial clinical experience
title_full Extracellular volume fraction mapping in the myocardium, part 2: initial clinical experience
title_fullStr Extracellular volume fraction mapping in the myocardium, part 2: initial clinical experience
title_full_unstemmed Extracellular volume fraction mapping in the myocardium, part 2: initial clinical experience
title_short Extracellular volume fraction mapping in the myocardium, part 2: initial clinical experience
title_sort extracellular volume fraction mapping in the myocardium, part 2: initial clinical experience
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3442966/
https://www.ncbi.nlm.nih.gov/pubmed/22967246
http://dx.doi.org/10.1186/1532-429X-14-64
work_keys_str_mv AT kellmanpeter extracellularvolumefractionmappinginthemyocardiumpart2initialclinicalexperience
AT wilsonjoelr extracellularvolumefractionmappinginthemyocardiumpart2initialclinicalexperience
AT xuehui extracellularvolumefractionmappinginthemyocardiumpart2initialclinicalexperience
AT bandettiniwpatricia extracellularvolumefractionmappinginthemyocardiumpart2initialclinicalexperience
AT shanbhagsujatam extracellularvolumefractionmappinginthemyocardiumpart2initialclinicalexperience
AT drueykirkm extracellularvolumefractionmappinginthemyocardiumpart2initialclinicalexperience
AT ugandermartin extracellularvolumefractionmappinginthemyocardiumpart2initialclinicalexperience
AT araiandrewe extracellularvolumefractionmappinginthemyocardiumpart2initialclinicalexperience